Comparing N-acetylcysteine and 4-methylpyrazole as antidotes for acetaminophen overdose

• Published in: Archives of toxicology Vol. 96; no. 2; pp. 453 - 465
• Main Authors: Akakpo, Jephte Y., Ramachandran, Anup, Curry, Steven C., Rumack, Barry H., Jaeschke, Hartmut
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.02.2022; Springer Nature B.V
• Subjects: Acetaminophen; Acetaminophen - poisoning; Acetylcysteine; Acetylcysteine - pharmacology; Analgesics; Analgesics, Non-Narcotic - poisoning; Animals; Antidotes; Antidotes - pharmacology; Biomedical and Life Sciences; Biomedicine; c-Jun protein; Chemical and Drug Induced Liver Injury - etiology; Chemical and Drug Induced Liver Injury - prevention & control; Clinical trials; Damage prevention; Drug Overdose; Environmental Health; Ethylene; Ethylene glycol; Fomepizole - pharmacology; Hepatocytes; Hepatocytes - drug effects; Hepatocytes - pathology; Hepatotoxicity; Humans; Ingestion; Injury prevention; Intravenous administration; JNK protein; Kidneys; Kinases; Liver; Liver diseases; Metabolism; Metabolites; Methanol; Mice; Occupational Medicine/Industrial Medicine; Overdose; Oxidants; Oxidizing agents; Patients; Pharmacology/Toxicology; Poisoning; Regeneration; Review Article; Transcription factors; Acetylcysteine; c-Jun N-terminal kinase; 4-Methylpyrazole; Acetaminophen; Hepatotoxicity; Fomepizole; N-Acetylcysteine
• ISSN: 0340-5761; 1432-0738
• DOI: 10.1007/s00204-021-03211-z

Acetaminophen (APAP) overdose can cause hepatotoxicity and even liver failure. N -acetylcysteine (NAC) is still the only FDA-approved antidote against APAP overdose 40 years after its introduction. The standard oral or intravenous dosing regimen of NAC is highly effective for patients with moderate overdoses who present within 8 h of APAP ingestion. However, for late-presenting patients or after ingestion of very large overdoses, the efficacy of NAC is diminished. Thus, additional antidotes with an extended therapeutic window may be needed for these patients. Fomepizole (4-methylpyrazole), a clinically approved antidote against methanol and ethylene glycol poisoning, recently emerged as a promising candidate. In animal studies, fomepizole effectively prevented APAP-induced liver injury by inhibiting Cyp2E1 when treated early, and by inhibiting c-jun N-terminal kinase (JNK) and oxidant stress when treated after the metabolism phase. In addition, fomepizole treatment, unlike NAC, prevented APAP-induced kidney damage and promoted hepatic regeneration in mice. These mechanisms of protection (inhibition of Cyp2E1 and JNK) and an extended efficacy compared to NAC could be verified in primary human hepatocytes. Furthermore, the formation of oxidative metabolites was eliminated in healthy volunteers using the established treatment protocol for fomepizole in toxic alcohol and ethylene glycol poisoning. These mechanistic findings, together with the excellent safety profile after methanol and ethylene glycol poisoning and after an APAP overdose, suggest that fomepizole may be a promising antidote against APAP overdose that could be useful as adjunct treatment to NAC. Clinical trials to support this hypothesis are warranted.